Customer Center
Login | Register

Investor Relations

  • Banner Image

News Releases

Date Title  
Toggle Summary Luminex Corporation Submits VERIGENE® II Respiratory Flex Assay for FDA Clearance
AUSTIN, Texas , Feb. 24, 2020 /PRNewswire/ --  Luminex Corporation  (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of the VERIGENE ® II Respiratory Flex Assay, the second VERIGENE II assay to be
Toggle Summary Luminex Corporation Declares First Quarter Cash Dividend
AUSTIN, Texas , Feb. 18, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2020 of $0.09 per share of common stock payable on April 9 , 2020 to stockholders of record as of the close
Toggle Summary Luminex Corporation to Participate At Upcoming Healthcare Investor Conferences in March 2020
AUSTIN, Texas , Feb. 13, 2020 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir , President & CEO, and Harriss Currie , Senior Vice President of Finance and CFO, plan to participate at three investor conferences in March 2020 .
Toggle Summary Luminex Corporation Reports Fourth Quarter and Full-Year 2019 Results
New Products and Effective Execution Support Return To Accelerated Organic Growth AUSTIN, Texas , Feb. 10, 2020 /PRNewswire/ --  Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2019 . All amounts in this release are in conformity
Toggle Summary Luminex Corporation To Release Fourth Quarter and Full-Year 2019 Results After Market Close On February 10, 2020
AUSTIN, Texas , Jan. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter and full-year ended December 31, 2019 on Monday, February 10, 2020 after the market close. The company will host a conference call that day at 5:00
Toggle Summary Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas , Jan. 12, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2019 highlights and 2020 guidance. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP").   Preliminary results, contained herein, are based on
Toggle Summary Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas , Dec. 6, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the fourth quarter of 2019 of $0.09 per share of common stock payable on January 15 , 2019 to stockholders of record as of the
Toggle Summary Luminex Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference on December 4, 2019
AUSTIN, Texas , Nov. 25, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Harriss Currie , Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Piper Jaffray 31 st Annual Healthcare Conference on Wednesday, December 4, 2019
Toggle Summary Luminex Corporation Reports Third Quarter 2019 Results and Submission of VERIGENE II Gastrointestinal Flex Assay to the FDA
AUSTIN, Texas , Nov. 4, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its third quarter ended September 30, 2019 . All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP").
Toggle Summary Luminex Corporation To Release Third Quarter 2019 Results After Market Close On November 4, 2019
AUSTIN, Texas , Oct. 25, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2019 on Monday, November 4, 2019 after the market close.  The company will host a conference call that day at 5:00 p.m.